Information Provided By:
Fly News Breaks for September 19, 2017
SUPN
Sep 19, 2017 | 07:37 EDT
As previously reported, Stifel analyst Annabel Samimy downgraded Supernus to Hold from Buy, as he believes the Phase 3 prospects of SPN-810, which is being studied to treat Impulsive Aggression, is already adequately reflected in the stock's current valuation. He keeps a $47 price target on Supernus shares.
News For SUPN From the Last 2 Days
There are no results for your query SUPN